Emeryville, CA, United States
Emeryville, CA, United States

Time filter

Source Type

Patent
NovaBay Pharmaceuticals | Date: 2015-08-20

The present invention relates generally to a magnetic valve system. Embodiments of the present invention provide a system to minimize the potential for mistakenly dispensing one fluid in place of another or desired fluid. More particularly, embodiments of the present invention provide a magnetic valve, where a bias mechanism is provided to bias the magnetic valve into a closed position, whereby a receptacle having a magnet with a magnetic polarity arranged opposite to that of the magnetic valve exerts a force on the magnetic valve sufficient to over come the bias mechanism, and the magnetic valve slides into an open position or state permitting fluid to flow into the receptacle. When the receptacle is removed, the bias mechanism forces the magnetic valve back into the closed position, where no or minimal fluid is permitted to flow.


News Article | May 11, 2017
Site: www.businesswire.com

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a pharmaceutical company focused on commercializing its prescription Avenova® lid and lash hygiene product for the domestic eye care market, reports financial results for the three months ended March 31, 2017 and provides a business update. “Avenova product sales for the quarter increased 165% over the prior year on record unit volume from our higher-margin prescription ophthalmology channel as we continued the effective implementation of our sales strategy,” said Mark M. Sieczkarek, NovaBay’s President and CEO. “Once again we achieved momentum among a range of key metrics, most notably with increases in the number of prescribing physicians and the average number of prescriptions per prescriber. We are therefore reaffirming our financial guidance for 2017. “We are committed to growing Avenova sales this year and beyond as we capitalize on the large market for blepharitis that we believe is poorly served by competing products and remedies,” he added. “Our strategy includes expanding our salesforce and investing in clinical studies to support physician adoption, while simultaneously managing expenses. We expect our current financial resources to be sufficient to fund operations and our growth strategy throughout 2017.” Net sales for the first quarter of 2017 increased 115% to $3.7 million from $1.7 million for the first quarter of 2016, due to higher Avenova product sales. Product revenue, which includes Avenova and NeutroPhase®, increased 123% to $3.7 million for the first quarter of 2017 from $1.7 million for the prior-year period. Total gross profit margin improved to 84% for the first quarter of 2017 from 64% for the first quarter of 2016 with the increase due to higher sales of Avenova. The gross profit margin on Avenova sales for the first quarter of 2017 was 88%. Operating loss for the first quarter of 2017 improved 19% to $3.8 million from $4.7 million for the first quarter of 2016. R&D expenses of $0.1 million for the first quarter of 2017 declined from $0.9 million for the first quarter of 2016, primarily due to the Company’s focus on Avenova commercialization. Sales and marketing expenses for the first quarter of 2017 were $3.7 million compared with $3.1 million for the prior-year period, with the increase primarily due to the transition to an in-house sales team and an increase in the number of sales representatives. G&A expenses for the first quarter of 2017 of $3.1 million compare with $1.7 million for the prior-year period, with the increase primarily resulting from higher stock-based compensation expense. The net loss for the first quarter of 2017 was $4.0 million, or $0.26 per share on a basic basis, compared with a net loss for the first quarter of 2016 of $5.1 million, or $1.24 per share on a basic basis. NovaBay reported cash and cash equivalents of $7.4 million as of March 31, 2017, compared with $9.5 million as of December 31, 2016. The Company used $2.0 million in cash to fund operations during the first quarter of 2017, a significant improvement from $4.9 million used during the first quarter of 2016. The decrease in cash usage was primarily due to higher sales of Avenova. NovaBay is affirming its financial guidance for 2017. The Company’s expectations are as follows: NovaBay management will host an investment community conference call today beginning at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss the Company’s financial and operational results and to answer questions. Shareholders and other interested parties may participate in the conference call by dialing 800-608-8202 from within the U.S. or 702-495-1913 from outside the U.S., with the conference identification number 14535369. A live webcast of the call will be available at http://novabay.com/investors/events and will be archived for 90 days. A replay of the call will be available beginning two hours after call completion through 11:59 p.m. Eastern time June 11, by dialing 855-859-2056 from within the U.S. or 404-537-3406 from outside the U.S. and entering the conference identification number 14535369. About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics® NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX® family of products and the AGANOCIDE® compounds. The Neutrox family of products includes AVENOVA® for the eye care market, NEUTROPHASE® for wound care market, and CELLERX® for the aesthetic dermatology market. The Aganocide compounds, still under development, have target applications in the dermatology and urology markets. Avenova is the Company’s main commercial focus. Data from a multicenter clinical study show that Avenova reduced bacterial load, the underlying cause of blepharitis, on ocular skin surface by more than 90%. Laboratory tests show that hypochlorous acid has potent antimicrobial activity in solution yet is non-toxic to mammalian cells and also neutralizes bacterial toxins. Avenova is marketed to optometrists and ophthalmologists throughout the U.S. by NovaBay’s direct salesforce. It is accessible from more than 90% of retail pharmacies in the U.S. through agreements with McKesson Corporation, Cardinal Health and AmerisourceBergen. This release contains forward-looking statements that are based upon management's current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding the size of our potential market, the future sales of our products, what we believe to be sufficient future financial resources, our expected gross margin, and generally the Company’s expected future financial results. Forward-looking statements can be identified with words like (and variations of): “believe,” and “expect.” These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to difficulties or delays in manufacturing, distributing, and selling the Company's products, unexpected adverse side effects or inadequate therapeutic efficacy of our product, the uncertainty of patent protection for the Company's intellectual property, and any potential regulatory problems. Other risks relating to NovaBay’s business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay's latest Form 10-K and Form 10-Q filings with the Securities and Exchange Commission, especially under the heading "Risk Factors." The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law. Stay informed on NovaBay's progress: Download our Mobile InvestorApp from the Apple Store or Google Play Like us on Facebook Follow us on Twitter Connect with NovaBay on LinkedIn Join us on Google+ Visit NovaBay's Website


News Article | May 19, 2017
Site: www.businesswire.com

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY) today announced receipt of a letter from NYSE MKT LLC (“NYSE MKT” or the “Exchange”) on May 16, 2017, stating that it is not in compliance with the continued listing standards (requiring stockholders’ equity of $6.0 million or more if it has reported losses from continuing operations and/or net losses in its five most recent fiscal years) as set forth in Section 1003(a)(iii) of the NYSE MKT Company Guide (“Company Guide”). In order to maintain its listing, NovaBay Pharmaceuticals must submit a plan of compliance by June 15, 2017, addressing how it intends to regain compliance with Section 1003(a)(iii) of the Company Guide. The Company intends to submit a plan to regain compliance with NYSE MKT listing standards. If the plan is not accepted, delisting proceedings will commence. If the plan is accepted, the Company’s common stock will continue to be listed on the NYSE MKT during the plan period. However, if the Company does not regain compliance with those standards or does not make progress consistent with the plan, the NYSE MKT staff may commence delisting proceedings. About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics® NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX® family of products and the AGANOCIDE® compounds. The Neutrox family of products includes AVENOVA® for the eye care market, NEUTROPHASE® for wound care market, and CELLERX® for the aesthetic dermatology market. The Aganocide compounds, still under development, have target applications in the dermatology and urology markets. Stay informed on NovaBay’s progress: Download our Mobile InvestorApp from the Apple Store or Google Play Like us on Facebook Follow us on Twitter Connect with NovaBay on LinkedIn Join us on Google+ Visit NovaBay’s Website


Dr. Shilpa Rose, an ophthalmologist at Whitten Laser Eye based in Washington, D.C., today is making a public service announcement about the problem of Dry Eye in patients undergoing refractive eye surgery - and how a new product, Avenova® Lid & Lash Hygiene by NovaBay Pharmaceuticals (NYSE MKT: NBY), can help manage this problem. An estimated 4,000,000 Americans every year undergo various types of eye surgery, such as LASIK and cataract surgery. By reshaping the cornea to treat nearsightedness, farsightedness, or astigmatism, LASIK has dramatically improved the vision-and quality of life-for millions of people. With the introduction of multifocal IOL's, cataract surgery patients are now able to retain their full range of vision. Whitten Laser Eye is one of the leading refractive surgical practices nationally, with many high profile patients, including Tiger Woods. Many of the patients coming in for surgery suffer from a condition known as meibomian gland dysfunction (MGD) Dry Eye, especially those who wear contact lenses. That's a problem for eye surgeons. "To get the best possible outcome in surgery, it is imperative that the surface of the eye is in optimal condition, which means first managing the patient's Dry Eye," explains Dr. Rose. "Fortunately, we are finding that we can successfully manage many of the variables of Dry Eye with Avenova®, an innovative daily lid and lash hygiene spray." Meibomian Gland Dysfunction Dry Eye is typically caused or exacerbated by tiny microbes-bacteria and parasitic mites that live on the eyelids. The microbes cause inflammation and block glands near the eye-the meibomian gland-from releasing a natural oil needed for the protective film of tears on the eyes. The microbes also produce lipase, an enzyme that breaks up the crucial oil. "As a result, the eyes lack the normal protective tear film," says Dr. Rose. "Not only can that be a painful and sometimes debilitating condition for patients, it also makes refractive eye surgery more difficult." Avenova directly tackles the major cause of Dry Eye. It is the only lid hygiene product to contain pure 0.01% hypochlorous acid, manufactured by the Neutrox method. Hypochlorous acid is naturally produced in our own white blood cells. In vitro testing shows that hypochlorous acid kills harmful bacteria and mites. It also blocks inflammatory agents released by both the bacteria and the body, and breaks up the enzyme lipase that attacks the tear-protection oil from the meibomian glands. "I love Avenova," says Dr. Rose. "Avenova provides an easy, safe and cost effective regimen to help manage MGD Dry Eye. Dr. Whitten and I now implement Avenova treatment for our refractive and cataract surgeries preoperatively and have been very pleased with the results."


Patent
NovaBay Pharmaceuticals | Date: 2016-05-10

Toxins produced by bacteria promote infection and disease by directly damaging host tissues and by disabling the immune system. In one embodiment, the present application provides methods of treating and prevention further inflammation by inactivating toxins through use positive chlorinated ionic solution and or their derivatives.


Patent
NovaBay Pharmaceuticals | Date: 2012-11-14

This application describes compounds useful as anti-microbial agents, including as antibacterial, disinfectant, antifungal, germicidal or antiviral agents.


Patent
NovaBay Pharmaceuticals | Date: 2014-10-31

The present invention relates generally to systems and methods for cleaning and disinfecting contact lenses. In various respects, the invention is directed to an insulated system that reduces heat loss from catalyzed neutralization of a disinfecting solution resulting in an increased temperature of the disinfection solution during the disinfection process and neutralization of the disinfection solution. The increased temperature increases the kill rate (i.e., better reduction) of microorganisms present on the lenses, and increases the neutralization rate of the disinfection solution. Increase of the kill rate allows better reduction of microorganisms resistant to elimination using previous systems and methods, (e.g., Acanthamoeba cysts), and decreases the amount of time as compared to previous systems and methods necessary to reduce microorganisms to acceptable levels.


Patent
NovaBay Pharmaceuticals | Date: 2016-05-27

Lipases produced by bacteria break down tear lipids and cause or exacerbate discomfort due to meibomian gland dysfunction, blepharitis or dry eye. In one embodiment, the present invention provides methods of treating and prevention further discomfort by inactivating lipases through use chlorinated solution and or their derivatives.


Patent
NovaBay Pharmaceuticals | Date: 2014-09-02

The invention monitors the neutralization process involving hydrogen peroxide solution and a hydrogen peroxide neutralization catalyst and compares measured values with theoretical values. The system monitors the chemical reaction and notifies the user of the neutralization status. In an exemplary embodiment, the initial hydrogen peroxide solution concentration is neutralized with a palladium catalyst after a period of time. A microcontroller analyzes the measurements and displays the neutralization process results using colored LED lights and/or text or images on a LCD display. In one embodiment, an apparatus adapted for use with a cleaning solution used to clean a medical device may include a trigger, a processing device in communication with the trigger, and a display device. The processing device provides a trigger count and the display device communicates with the processing device and displays a message based on the count.


Patent
NovaBay Pharmaceuticals | Date: 2014-04-30

The present invention relates to active bactericidal, antibacterial, anti-infective, antimicrobial, sporicidal, disinfectant, antifungal and antiviral compounds and compositions and to new uses of these compositions in therapy. This specification also describes methods of use for the new compounds and compositions. The specification further describes methods for preparing these compounds.

Loading NovaBay Pharmaceuticals collaborators
Loading NovaBay Pharmaceuticals collaborators